.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,512,745

« Back to Dashboard

Claims for Patent: 8,512,745

Title:Ulipristal acetate tablets
Abstract: The invention relates to a pharmaceutical tablet for oral administration comprising ulipristal acetate together with the following excipients: a diluent in an amount of 60 to 95 wt %, a binding agent in an amount of 1 to 10 wt %, croscarmellose sodium in an amount of 1 to 10 wt %, and magnesium stearate in an amount of 0 to 5 wt %.
Inventor(s): Gainer; Erin (Paris, FR), Guillard; Helene (Paris, FR), Gicquel; Denis (Orgeval, FR), Henrion; Marianne (Paris, FR), Gnakamene; Celine (Paris, FR)
Assignee: Laboratoire HRA Pharma (Paris, FR)
Application Number:12/329,865
Patent Claims: 1. A pharmaceutical tablet for oral administration comprising: 3 to 18 wt % of ulipristal acetate, wherein ulipristal acetate is present in the tablet in an amount ranging from 5 mg to 50 mg, 60 to 95 wt % of a diluent selected from the group consisting, of lactose monohydrate and mannitol, 1 to 10 wt % of a binding agent selected from the group consisting of hydroxypropyl methyl cellulose and povidone, 1 to 10 wt % of croscarmellose sodium, and 0 to 5 wt % magnesium stearate, wherein the tablet is an oral tablet and is uncoated, and wherein at least about 90% (w/w) of ulipristal acetate present in the tablet is dissolved within about 20 minutes when the tablet is subjected to an in vitro dissolution assay according to the general monograph of the European Pharmacopoeia .sctn.2.9.3, at 37.degree.C..+-.0.5.degree.C., a rotation speed of 50 rpm and pH=1.

2. The tablet of claim 1, wherein the dUuent is in an amount of 65 to 92 wt %.

3. The tablet of claim 1, wherein the binding agent is in an amount of 1.5 to 8.5 wt %.

4. The tablet of claim 1, wherein croscarmellose sodium is in an amount of 1.5 to 8.5 wt %.

5. The tablet of claim 1, wherein magnesium stearate is in an amount of 0.5 to 4 wt %.

6. The tablet according to claim comprising 10 wt % ulipristal acetate.

7. The tablet according to claim 1, comprising 5 to 30 mg ulipristal acetate.

8. The tablet according to claim 1, wherein the diluent is lactose monohydrate and the binding agent is povidone.

9. The tablet according to claim 1, comprising ulipristal acetate 6 to 12 wt %, lactose monohydrate 71 to 87 wt %, povidone 4.5 to 5.5 wt %, croscarmellose sodium 4.5 to 5.5 wt % and magnesium stearate 1 to 4 wt %.

10. The tablet of claim 9, comprising ulipristal acetate 10 wt %, lactose monohydrate 79 wt %, povidone 5 wt %, croscarmellose sodium 5 wt % and magnesium stearate 1 wt %.

11. A method of manufacturing the tablet according to claim 1, the method comprising mixing the ingredients and ulipristal acetate and forming a tablet.

12. The tablet of claim 1, comprising 5 mg ulipristal acetate.

13. The tablet of claim 1, comprising 10 mg ulipristal acetate.

14. The tablet of claim 1, comprising 15 mg ulipristal acetate.

15. The tablet of claim 1, comprising 20 mg ulipristal acetate.

16. The tablet of claim 1, comprising 30 mg ulipristal acetate.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc